Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A two-drug combination simulation study for metastatic castrate resistant prostate cancer.

The Prostate - 1 Nov 2018

Root Alex, Ebhardt H Alexander

Abstract excerpt

BACKGROUND: Prostate cancer often evolves resistance to androgen deprivation therapy leading to a lethal metastatic castrate-resistant form. Besides androgen independence, subpopulations of the tumor are genetically heterogeneous. With the advent of tumor genome sequencing we asked which has the greater influence on reducing tumor size: genetic background, heterogeneity, or drug potency? METHODS: A previously...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Computer Simulation
Share to Models, Biological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Mutation

Share to Neoplasm Metastasis

Share to Prostatic Neoplasms, Castration-Resistant

Source

Open in PubMed Open full text

Identifiers

PMID: 30027544
DOI: 10.1002/pros.23694
PMCID: PMC6519289

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A two-drug combination simulation study for metastatic castrate resistant prostate cancer.PMID 30027544Read ↗

Divergent Clonal Evolution and Early Dissemination Promote Genetic Heterogeneity of Metastases in Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

The time for molecular phenotyping of metastatic castrate-resistant prostate cancer is now.Semantic proximity Read ↗

Mutational Landscapes of Sequential Prostate Metastases and Matched Patient Derived Xenografts during Enzalutamide Therapy.Semantic proximity Read ↗

Comparison of Real-World Outcomes between Patients with BRCA1/2-Positive and Homologous Recombination Repair-Negative Metastatic Castration-Sensitive Prostate CancerSemantic proximity Read ↗

Multi-gene mutation metastatic castrate-resistant prostate cancer.Semantic proximity Read ↗

The Mutational Landscape of Metastatic Castration-sensitive Prostate Cancer: The Spectrum Theory Revisited.Semantic proximity Read ↗

Treatment Sequencing in Metastatic Castration-Resistant Prostate Cancer: A Clinical Commentary.Semantic proximity Read ↗

Beyond simple castration: targeting the molecular basis of treatment resistance in advanced prostate cancerSemantic proximity Read ↗

Evolution of Castration-Resistant Prostate Cancer in ctDNA during Sequential Androgen Receptor Pathway InhibitionSemantic proximity Read ↗

Coupled Cell-Intrinsic and Microenvironmental Heterogeneity Drives Divergent Trajectories in Castration-Resistant Prostate CancerSemantic proximity Read ↗

Androgen receptor enhancer amplification in matched patient‐derived xenografts of primary and castrate‐resistant prostate cancerSemantic proximity Read ↗

Immune evasion in prostate cancer: resolving the cold tumour paradox via a hybrid discrete-continuum computational frameworkSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.